Combination therapy and sequential therapy with interferons and nucleos( t) ide analogues against HBV

Currently,there are two categories of antiviral drugs used for chronic hepatitis B( CHB) : interferons( IFNs) and nucleos( t) ide analogues( NAs). IFNs showed lower efficacy and more adverse effects,although they achieved some anti- HBV results. NAs showed stronger antiviral activity and a lower incidence rate of adverse effects; however,there are also some problems,such as high risk of relapse after the NAs are discontinued and increased rate of drug resistance with a longer course of treatment. Therefore,it is very important for clinicians to investigate the optimal therapy against HBV to further improve efficacy and safety in the treatment of CHB. In this paper,the research on combination therapy and sequential therapy against HBV is reviewed,in the hope that clinicians may have a deeper knowledge of combination therapy and sequential therapy against HBV,so as to provide more choices for antiviral therapy of CHB patients.